Drug Profile
PV 702
Latest Information Update: 22 Sep 2004
Price :
$50
*
At a glance
- Originator CRC for Tissue Growth and Repair (CEASED)
- Class Antiulcers
- Mechanism of Action Intercellular signalling peptide and protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Varicose ulcer
Most Recent Events
- 05 Apr 2004 Discontinued - Phase-II for Varicose ulcer in Australia (Topical)
- 31 Jul 2003 GroPep has completed enrolment in a phase II trial for Varicose ulcers in Australia
- 18 Feb 2003 This compound is still in active development